Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | UGCG | Q16739 | 2/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | OSBP | P22059 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14046807 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14534344 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL17468531 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL863221 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14538772 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL24141906 | 1.00 | POLA1 (0.50) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14554227 | 0.98 | POLA1 (0.51) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL22757123 | 0.95 | POLA1 (0.49) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL14878927 | 0.94 | POLA1 (0.46) | POLA1CYP46A1GBA1UGCGGBA2 | |
| SCHEMBL16995494 | 0.94 | POLA1 (0.44) | POLA1CYP46A1GBA1UGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2025-05-29 | — | — | US | disclosed |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM EUROPE AG (DE) | 2024-03-21 | — | — | US | disclosed |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230053332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20060217324-A1 | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof | ALNYLAM PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | BANK OF AMERICA, N.A. | 2006-05-18 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | BANK OF AMERICA, N.A. | 2006-03-16 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217324-A1 | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof | RTN4, RTN3, GAP43 | POLA1 4156/4885CYP46A1 4408/4885GBA1 595/4885 |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | NSUN2, RNMT, RNGTT | POLA1 863/4885CYP46A1 5/4885GBA1 3656/4885 |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | APOB, LDLR, APOL1 | POLA1 2783/4885CYP46A1 159/4885GBA1 519/4885 |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | SAAL1, APOB, SCARB1 | POLA1 1641/4885CYP46A1 130/4885GBA1 340/4885 |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, SCARB1 | POLA1 1641/4885CYP46A1 130/4885GBA1 340/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | POLA1 257/4885CYP46A1 3475/4885GBA1 575/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | POLA1 657/4885CYP46A1 3979/4885GBA1 499/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | POLA1 261/4885CYP46A1 4324/4885GBA1 1539/4885 |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | RHOA, RHOC, ARHGDIA | POLA1 2346/4885CYP46A1 1413/4885GBA1 1805/4885 |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | HTT, HYPK, DHX36 | POLA1 256/4885CYP46A1 4172/4885GBA1 107/4885 |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | EGFR, ERBB3, ERBB2 | POLA1 923/4885CYP46A1 4216/4885GBA1 2503/4885 |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | POLA1 662/4885CYP46A1 847/4885GBA1 1021/4885 |
| US-20230053332-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | EGFR, ERBB3, ERBB2 | POLA1 923/4885CYP46A1 4216/4885GBA1 2503/4885 |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | POLA1 326/4885CYP46A1 80/4885GBA1 244/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | POLA1 879/4885CYP46A1 880/4885GBA1 124/4885 |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | RHOA, ARHGDIA, RHOC | POLA1 2746/4885CYP46A1 1564/4885GBA1 1605/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | POLA1 917/4885CYP46A1 1935/4885GBA1 566/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | POLA1 1142/4885CYP46A1 4277/4885GBA1 863/4885 |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | POLA1 326/4885CYP46A1 80/4885GBA1 244/4885 |
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, APOB, APOL1 | POLA1 2259/4885CYP46A1 193/4885GBA1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.